Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group

Volker Heinemann(LMU Klinikum), Nicolas Moosmann(Praxis für Hämatologie und Onkologie), Daniel Oruzio(Praxis für Hämatologie und Onkologie), Martina Stauch, U. Vehling-Kaiser(University of Applied Sciences Landshut), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Joseph B. Weiss(University of North Carolina Health Care), Manfred Schulze, Hermann Dietzfelbinger, Holger G. Hass(Paracelsus-Kliniken)

Journal of Clinical Oncology

May 20, 2008

10.1200/jco.2008.26.15_suppl.4033

Cited by 14

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

|European Journal of Cancer|2016|533